Study | Number of patients | Diagnosis | Duration of lithium treatment | Outcome measured | Follow-up | Results |
---|---|---|---|---|---|---|
Goodwin et al. (2004) | 167 (166 completed) lithium 280 (227 completed) lamotrigine 191 (190 completed) placebo | BD1 | NA | Self-reported incidence of new-onset skin disorders during treatment | 18-months | Lithium: 5% Lamotrigine: 7% Placebo: 5% |
Geller et al. (2012) | 89 risperidone 90 (84 completed) lithium 100 (97 completed) valproic acid | BD1 | NA | Systematic structured assessment of side effects | 8 weeks | Lithium: 6% Risperidone: 6.7% Valproic acid: 13.4% |
NCT01189812 | 40 citalopram + placebo 40 citalopram + lithium | MDD, Dysthymia DNOS, BPD | 4 weeks | Self-reported incidence of new-onset skin disorders during treatment | 4 weeks | Citalopram + lithium: 2.5% Citalopram + placebo: 2.5% |